BioSpace News Archive

BostonGene announced today the launch of its CLIA-certified and CAP-accredited Liquid Biopsy, Immunoprofiling and Spatial Proteomics solutions that provide a holistic view of a patient’s disease by integrating multiple AI-based molecular and immune profiling techniques that analyze tumor, microenvironment, and host immunity.

CureALS, a pioneering nonprofit organization dedicated to eliminating ALS and other complex neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Frontotemporal Dementia, has officially launched.

International medical imaging IT and cybersecurity company Sectra reports that sales and operating profit for the fourth quarter and for the fiscal year exceeded previous records and recurring revenue increased.

IVBH, a leader in liquid biopsy technology, specializing in noninvasive early detection, will unveil groundbreaking data from an independent validation study of the company’s proprietary LiquidLung lung cancer detection technology, at the ASCO® 2023 Annual Meeting.

Quest Diagnostics Incorporated, the world’s leading provider of diagnostic information services, announced that it is scheduled to speak at the Jefferies Global Healthcare Conference.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a non-brokered private placement of up to 10 Million Units priced at $0.12 each, closing in tranches.

A new approach to building AI with an automated AI App Builder for scientists to remove noise and complexity in Mass Spectrometry analysis

Theratechnologies Inc. today announced that the U.S. Food and Drug Administration (FDA) has agreed to the Company’s amended protocol for the Phase 1 clinical trial of sudocetaxel zendusortide, an investigational, first-in-class peptide-drug conjugate (PDC) that targets the sortilin (SORT1) receptor and expedites the internalization and delivery of a cytotoxic payload directly into cancer cells.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced today that, with sponsorship and support from multiple physician specialty societies, the American Medical Association (“AMA”) has established three new Current Procedural Terminology (“CPT®’) Category 1 codes for MRI-Monitored Transurethral Ultrasound Ablation (“TULSA”) of prostate tissue, performed using Profound’s TULSA-PRO® system.

Promontory Therapeutics Inc. announces preliminary data from a Phase 2 clinical trial of the company’s lead therapeutic candidate, PT-112, in patients with recurrent thymic epithelial tumors (TETs), specifically thymoma and thymic carcinoma.